BioNTech said in 2022 that it faced “threats of a groundless patent infringement suit” from a company that was “unable to ...

The Ministry of Health has announced that the updated Pfizer-BioNTech Covid-19 vaccine, targeting the JN.1 variant, is now available in Bermuda by appointment. A Government spokesperson said, “The ...

An updated Pfizer-BioNTech Covid-19 vaccine, designed to target the JN.1 variant of the virus circulating globally, is now ...

BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech ...

Valued at $1.25 billion, the deal expands BioNTech’s cancer drug portfolio and heads off royalty costs it could have owed ...

CureVac (CVAC) stock jumps as BioNTech (BNTX) agrees to acquire in an all-stock deal worth $1.25B. Read more here.

(Reuters) -Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune ...

CureVac about a year ago opted to focus on oncology when it agreed to sell its remaining influenza and COVID-19 vaccine ...

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, the companies said Thursday, bringing together two ...

German pharmaceutical firm BioNTech, one of the first companies worldwide to develop an effective coronavirus vaccine, is looking to acquire its domestic rival CureVac, the firm said on Thursday.